HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Cl958

a benzothiopyranoindazole; structure in first source

Also Known As:

Cl-958; NSC 635371; NSC635371

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Cl958: 3

Experts

1.	Kraut, Eric: 1 article (04/2004)
2.	Moore, Timothy: 1 article (04/2004)
3.	Philip Kuebler, J: 1 article (04/2004)
4.	Pritchard, James: 1 article (04/2004)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 01/01/1999 - "We completed a phase II trial of CI-958 (NSC 635371) in patients with advanced colorectal cancer given at a dose of 700 mg/m2 every 21 days. "
2.	Carcinoma (Carcinomatosis) 04/01/2004 - "A phase II trial of CI-958 (NSC #635371), a new benzothiopyranoindazole was performed in patients with hormone refractory prostate carcinoma using prostate specific antigen (PSA) levels for response assessment. "
3.	Neoplasms (Cancer) 01/01/1988 - "Cl-958, PD 121373, and PD 114595 belong to a new class of DNA complexers, substituted 2H-[1]benzothiopyrano[4,3,2-cd] indazoles, and are being further developed as antitumor drugs based on their curative properties against murine solid tumor models. "

Related Drugs and Biologics

1.	ledoxantrone
2.	Prostate-Specific Antigen (Semenogelase)
3.	Hormones (Hormone)
4.	Indazoles
5.	DNA (Deoxyribonucleic Acid)
6.	Antineoplastic Agents (Antineoplastics)
7.	PD 121373
8.	PD 114595